Pear Therapeutics debtor reports $22,609 net loss for March

By Sarah Lizee

Olympia, Wash., April 15 – Pear Therapeutics, Inc. debtor Pear Therapeutics US, Inc. reported a $22,609 net loss for March on zero gross income/sales, according to its monthly operating report filed Friday with the U.S. Bankruptcy Court for the District of Delaware.

The cash balance at the end of the month was $8.78 million.

Boston-based Pear Therapeutics develops and commercializes software-based medicines called prescription digital therapeutics. The company filed bankruptcy on April 7, 2023 under Chapter 11 case number 23-10429.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.